The Annual Scientific Meeting 2025 of
The Hong Kong Society of Biological Psychiatry

Cutting Edge in Psychiatry

November 8-9th, 2025

4/F, Bauhinia Room,
Marco Polo Hong Kong Hotel, Harbour City,
3 Canton Road, Tsim Sha Tsui

Our Key Speakers

Dr. LO Tak Lam, William
Specialist in Psychiatry

Dr. CHUNG Kar Kin, Albert
Clinical Assistant Professor,
Department of Psychiatry,
The University of Hong Kong

Dr. FU Kit Yu, Amy
Division of Life Science and State Key Laboratoryof Nervous System Disorders,
The Hong Kong University of Science and Technology

Dr. NG Chong Guan
Specialist in Psychiatry,
Klinik Pakar Linda & Ng SDN.BHD.,
Mental Health Specialist, Malaysia

Dr. CHU Yim Pui, Jonathan
Specialist in Neurology

Dr. HUANG Bei, Joanne
Research Assistant Professor,
Department of Psychiatry,
The Chinese University of Hong Kong

The Annual Scientific Meeting 2025 of
The Hong Kong Society of Biological Psychiatry

Cutting Edge in Psychiatry

Table of Content

Welcome Message

On behalf of the Organizing Committee, it is my pleasure to warmly welcome you to the **Annual Scientific Meeting 2025 of the Hong Kong Society of Biological Psychiatry (HKSBP)**, taking place on **November 8-9th, 2025** (Saturday and Sunday) at the esteemed **Marco Polo Hong Kong Hotel**.

This year's theme, **Cutting Edge in Psychiatry**, highlights the latest advancements and research that are shaping our understanding and practices in the field. We are honored to present an impressive lineup of distinguished speakers who will share their valuable insights and expertise.

The agenda begins on Saturday evening with a session by **Dr. LO Tak Lam, William** on **"Managing Anhedonia in MDD Patients."** On Sunday, we will feature a series of thought-provoking lectures:

- **Lecture 1** by **Dr. CHUNG Kar Kin, Albert** will address **"Cutting-edge Treatment for Cannabis and Stimulant Use and Related Disorders from Hong Kong."**

- **Lecture 2** presented by **Dr. FU Kit Yu, Amy** will focus on **"Discovering Blood Biomarkers for Early Detection of Alzheimer's Disease and Amyloid Pathology Indication."**

- During our Lunch Symposium, **Dr. NG Chong Guan** will discuss the **"Rational Use of Antipsychotics for MDD Augmentation,"** exploring how dopamine partial agonists can enhance treatment outcomes.

- **Lecture 3, "Translating 48-Month Lecanemab Data into Real-World Practice: Advancing Precision Treatment in Alzheimer's Disease,"** will be delivered by **Dr. CHU Yim Pui, Jonathan**.

- Lastly, **Dr. HUANG Bei, Joanne** will deliver **Lecture 4**, which will examine **"The Gut-Brain Axis in Prodromal Synucleinopathy: Insights from a Hong Kong iRBD Cohort."**

We look forward to your participation in what promises to be an enlightening and intellectually enriching event. Together, let us advance our knowledge and contribute to the future of psychiatry.

Your Sincerely,

Dr. LO Ka Ying, Heidi
Chairperson, Organizing Committee of ASM 2025
Hong Kong Society of Biological Psychiatry

Annual Scientific Meeting 2025 Organizing Committee

Chairperson of Organizing Committee:	**Dr. LO Ka Ying, Heidi**
Members:	**Dr. CHUNG Kar Kin, Albert**
	Prof. WING Yun Kwok
	Dr. WONG Ming Cheuk, Michael
	Dr. CHEUNG Hon Kee, Henry
	Dr. TSANG Suk Kwan, Jenny
	Dr. LO Chun Wai
	Prof. TANG Siu Wa
	Dr. WONG Chung Hin, Willy

HKSBP Council Member 2024-2025

Executive Committee:

Current Past and Founding President:	**Prof. TANG Siu Wa**
President:	**Dr. WONG Ming Cheuk, Michael**
Vice President :	**Dr. CHUNG Kar Kin, Albert**
Honorary Secretary:	**Dr. CHEUNG Hon Kee, Henry**
Honorary Treasurer:	**Dr. TSANG Suk Kwan, Jenny**
Committee Members:	**Dr. IU Pui Chuen**
	Dr. LO Chun Wai
	Dr. LO Ka Ying, Heidi
	Prof. WING Yun Kwok
	Dr. WONG Chung Hin, Willy

Cutting Edge in Psychiatry

Floor Plan



The Annual Scientific Meeting 2025 of
The Hong Kong Society of Biological Psychiatry

Cutting Edge in Psychiatry

Floor Plan





Cutting Edge in Psychiatry
Scientific Programme

Time	November 8th, 2025, Saturday	Venue
18:30	Registration	Foyer, Level 4
19:00-22:00	**Dinner Symposium: Managing Anhedonia in MDD Patients** **Dr. LO Tak Lam, William** Specialist in Psychiatry **Chairperson: Dr. WONG Ming Cheuk, Michael, Specialist in Psychiatry** *(Sponsored by Lundbeck Hong Kong)*	Bauhinia Room, Level 4
Time	**November 9th, 2025, Sunday**	**Venue**
09:30	Registration & Coffee	Foyer, Level 4
09:30-10:00	AGM *(For HKSBP Members ONLY)*	Bauhinia Room, Level 4
10:00-11:00	**Lecture 1: Cutting-edge Treatment for Cannabis and Stimulant Use and Related Disorders from Hong Kong** **Dr. CHUNG Kar Kin, Albert** Clinical Assistant Professor, Department of Psychiatry, The University of Hong Kong **Chairperson: Dr. CHEUNG Kin Leung, Ben, Specialist in Psychiatry**	Bauhinia Room, Level 4
11:00-11:30	Exhibition & Coffee	Foyer, Level 4
11:30-12:15	**Lecture 2: Discovering Blood Biomarkers for Early Detection of Alzheimer's Disease and Amyloid Pathology Indication** **Dr. FU Kit Yu, Amy** Division of Life Science and State Key Laboratory of Nervous System Disorders, The Hong Kong University of Science and Technology **Chairperson: Dr. YAU Suk Yu, Sonata, Associate Professor, Department of Rehabilitation Sciences, Hong Kong Polytechnic University**	Bauhinia Room, Level 4
12:30-14:15	**Lunch Symposium: Rational Use of Antipsychotics for MDD Augmentation. How Does Dopamine Partial Agonist Unlock the Hidden Potential to Enhance Treatment Outcome?** **Dr. NG Chong Guan** Specialist in Psychiatry, Klinik Pakar Linda & Ng SDN.BHD., Mental Health Specialist, Malaysia **Chairperson: Dr. CHEUNG Hon Kee, Henry, Specialist in Psychiatry** *(Sponsored by Otsuka)*	Jade & Lotus Room, Level 6
14:30-15:15	**Lecture 3: Translating 48-Month Lecanemab Data into Real-World Practice: Advancing Precision Treatment in Alzheimer's Disease** **Dr. CHU Yim Pui, Jonathan** Specialist in Neurology **Chairperson: Dr. LO Ka Ying, Heidi, Clinical Assistant Professor, Department of Psychiatry, The University of Hong Kong** *(Sponsored by Eisai)*	Bauhinia Room, Level 4
15:15-15:45	Exhibition & Coffee	Foyer, Level 4
15:45-16:30	**Lecture 4: The Gut-Brain Axis in Prodromal Synucleinopathy: Insights from a Hong Kong iRBD Cohort** **Dr. HUANG Bei, Joanne** Research Assistant Professor, Department of Psychiatry, The Chinese University of Hong Kong **Chairperson: Dr. TSANG Suk Kwan, Jenny, Specialist in Psychiatry**	Bauhinia Room, Level 4
16:30-17:00	Mingle and Farewell	Foyer, Level 4

Dinner Symposium: Managing Anhedonia in MDD Patients
19:00-20:30, November 8th, 2025, Saturday

Dr. LO Tak Lam, William

Dr. LO is currently a Private Psychiatrist at Alliance Medical Centre. He was the Service Director (Mental Health) & Cluster Chief Executive Delegate (Human Resources) of Kowloon West Cluster as well as the Hospital Chief Executive & Consultant Psychiatrist in Kwai Chung Hospital till Jan 2019. Before taking HCE role, he was the Chief of Service & Consultant Psychiatrist in Kwai Chung Hospital from 1994.
Dr. LO is an Honorary Clinical Associate Professor, Department of Psychiatry in both The University of Hong Kong and The Chinese University of Hong Kong. He is also an Honorary Clinical Associate Professor, Family Medicine Unit, The Chinese University of Hong Kong and an Associate Director, Centre of Suicide Research & Prevention, The University of Hong Kong. He is an Honorary Clinical Supervisor, The Hong Kong College of Family Physicians and had been a Psychiatric Trainer/Tutor of The Royal College of Psychiatrists and The Hong Kong College of Psychiatrists. In addition, he saved as a Member of Rehabilitation Advisory Committee, Labour and Welfare Bureau, a Member of the Executive Committee in the Quality Education Fund Thematic Network (QTN) on Developing Students Positive Attitudes and Values, Centre for Suicide Research and Prevention, The University of Hong Kong and a Disciplinary Committee Panel Member, Social Workers' Registration Board.
Dr. LO participates in various community services and is currently Chairman, Mental Health Association of Hong Kong. He is also a Chairman, Institute of Community Rehabilitation, Mental Health Association of Hong Kong and a Director, Board of Directors, Haven of Hope Christian Service. Besides, Dr LO is a Director, Mentalcare Connect Company Limited, Mental Health Association of Hong Kong.

Dr. LO obtained his MBBS in 1983 from The University of Hong Kong and his MRCPsych in 1989, he received postgraduate training in The University Department of Psychiatry at Warneford Hospital, Oxford, United Kingdom. He became Foundation Fellow of The Hong Kong College of Psychiatrists in 1990 as well as Fellow of The Hong Kong Academy of Medicine in Psychiatry in 1993. He has been a past Vice President (Censor & Education) of The Hong Kong College of Psychiatrists (2003-2006) and was elected Fellow of The Royal College of Psychiatrists in 2009. He has published over 70 articles in psychiatry and patient care.

Abstract

Good clinical response and functional recovery of Major Depressive Disorder are far from satisfactory in real life situations. This presentation addresses the critical management of anhedonia in Major Depressive Disorder (MDD), a core symptom that profoundly affects the ability to experience pleasure and engage in daily activities. Anhedonia impacts about 75% of MDD patients, complicating treatment outcomes even during remission. The role of antidepressants, particularly vortioxetine, which has shown significant efficacy in alleviating anhedonia hence improving overall functioning will be discussed. Understanding the dose-response relationship is essential in the use of antidepressants, higher dose may enhance therapeutic effects but also increase the risk of side-effects. Personalised treatment strategies that consider both the pharmacological properties of medications and clinical response of individual patients should be carefully formulated. It underscores the importance of a tailored approach to optimise outcomes in managing anhedonia hence improving the treatment of depression.

Lecture 1: Cutting-edge Treatment for Cannabis and Stimulant Use and Related Disorders from Hong Kong

10:00-11:00, November 9th, 2025, Sunday

Dr. CHUNG Kar Kin, Albert

Dr. Albert Chung is a Clinical Assistant Professor in the Department of Psychiatry, University of Hong Kong and is the psychiatrist in-charge of the Substance Abuse Clinic Services at Queen Mary Hospital, Hong Kong West Cluster. Passionate in teaching, he also serves as the Director of Education, Problem-based Learning Educator and Chief Examiner in the School of Clinical Medicine in the University of Hong Kong.

In addition, Dr. Chung is appointed as the Vice-President for the Hong Kong Society of Biological Psychiatry and serves as advisory group members in various government committees.

Dr. Chung was conferred fellowship with the Hong Kong Academy of Medicine and the Hong Kong College of Psychiatrists in 2010. He won the Distinguished Young Fellow award by the Hong Kong College of Psychiatrists in 2015. His research interests reside in clinical psychopharmacology, pharmacological and non-pharmacological interventions in substance misuse psychiatry (Substance misuse To Psychiatric disorders Program—"SToP Program").

Abstract

Cannabis and stimulants are commonly misused illicit drugs worldwide. Their misuses have worrying mental health implications. The potential bidirectional associations between mood symptoms and cannabis use have long been postulated. The prevalence of stimulant-associated psychosis for cocaine and methamphetamine is reported to be as high as 40% and 60%, respectively. Both cannabis and stimulant misuses substantially elevate the risk of developing schizophrenia as well. Up to date, limited evidence exists for pharmacotherapy in managing cannabis or stimulant use disorders and their associated psychiatric comorbidities, or on physical treatment in managing cannabis use disorder. The current presentation focuses on pharmacotherapy and physical treatment for treating cannabis and stimulant misuses, and their related psychiatric comorbidities based on the latest evidence from the Substance misuse To Psychiatric disorders (SToP) Program in Hong Kong.

Lecture 2: Discovering Blood Biomarkers for Early Detection of Alzheimer's Disease and Amyloid Pathology Indication

11:30-12:15, November 9th, 2025, Sunday

Dr. FU Kit Yu, Amy

Dr. Amy Kit-Yu FU is a Research Professor in the Division of Life Science and State Key Laboratory of Nervous System Disorders, as well as the Associate Director of Daniel and Mayce Yu Molecular Neuroscience Center, and the Center for Stem Cell Research, at the Hong Kong University of Science and Technology (HKUST). She also serves as the R&D Director of the Hong Kong Center for Neurodegenerative Diseases, an InnoHK Center.

Her research primarily focuses on understanding the mechanisms of Alzheimer's disease (AD) and developing therapeutic strategies. Notable contributions to the field include her discoveries regarding the roles of cell-surface receptors in impaired synaptic functions and plasticity in AD, as well as insights into the mechanisms by which microglia fail to clear pathological amyloid-beta, a hallmark of AD. Dr. Fu has expanded her research to human studies of AD, encompassing genomic, proteomic, and endophenotype analyses. Her work in identifying novel biomarkers of AD has addressed a critical knowledge gap, providing valuable insights into disease diagnosis and target discovery. Additionally, she has extensive experience in drug discovery research.

Abstract

Alzheimer's disease (AD), the most prevalent form of dementia, is characterized by the accumulation of extracellular amyloid-beta (Aβ) plaques and neurofibrillary tangles. Detecting early-stage AD and identifying individuals with mild cognitive impairment (MCI) who show evidence of Aβ pathology in the brain can significantly aid in disease management. This underscores the urgent need for simple, accurate, and minimally invasive diagnostic methods, such as blood tests, to facilitate the early detection of AD and MCI. Accordingly, we conducted the first comprehensive screening of blood protein biomarkers for AD, establishing a set of biomarkers that reflect various biological pathways associated with the disease. We then integrated these AD blood protein biomarkers into an assay chip, developing a multiprotein diagnostic test for AD. This blood-based test accurately identifies MCI and early-stage AD in individuals of both Chinese and European descent populations. Compared to existing pathological biomarkers, this test provides a comprehensive analysis of multiple biological pathways related to AD. Furthermore, the ability to detect and assess Aβ pathological changes in the brain is crucial for accurate detection and staging of AD. To achieve this, we thoroughly profiled the dynamics of the plasma proteome in relation to Aβ accumulation and developed a blood biomarker assay for detection, monitoring, and staging of Aβ pathology. In summary, blood-based biomarker test represents a valuable resource for the early detection, classification, and staging of AD.

Lunch Symposium: Rational Use of Antipsychotics for MDD Augmentation. How Does Dopamine Partial Agonist Unlock the Hidden Potential to Enhance Treatment Outcome?

12:30-13:30, November 9th, 2025, Sunday

Dr. NG Chong Guan

Dr. Ng Chong Guan is a former Professor and Consultant Psychiatrist at the University of Malaya in Kuala Lumpur, Malaysia.
He is also the Deputy President of the Malaysian Mental Health Association and Treasurer of the Malaysian Psychiatric Association.
Shortly after completion of his master training in psychological medicine in 2009, Dr. Ng was awarded a scholarship from the European Union (via AsiaLink) to do his second master degree in clinical epidemiology and evidence-based medicine; and his first Doctorate of Philosophy (PhD) study at Utrecht University in The Netherlands.
In 2017, he completed another Doctorate Degree in Medicine (MD) in psycho-oncology in University Malaya.
He has just completed his third master degree in health research ethics (MOHRE) in University of Malaya under the scholarship of Fogarty International Center of the United States, National Institutes of Health in collaboration with the Berman Institute of Bioethics, Johns Hopkins University.
Dr. Ng is the Editor-in-Chief of the Malaysian Journal of Psychiatry, has published numerous articles in prestigious medical journals, and is a regular speaker at local and international conferences.
To date, Dr. Ng has more than 100 international publications with H Index of 22 and more than 1700 citations. He is listed as one of the World Top 2% Scientists 2022 based on the in the report from Stanford University.

Abstract

Major depressive disorder (MDD) has a global prevalence of 163 million and is among the leading causes of years lived with disability. In clinical trials, numerous antidepressant treatments (ADTs) have demonstrated efficacy versus placebo on depressive symptoms. Nonetheless, many individual patients fail to respond to adequate courses of ADT. 1 In this lecture, Dr. Ng will illustrate the role of antipsychotic augmentation as one of the treatment options for MDD patients with inadequate response to ADTs. Second generation antipsychotics with the properties of Serotonin-dopamine activity modulator (SDAM) hypothesis with its mechanism of action of partial agonism at serotonin 5-HT 1A and dopamine D 2 receptors at similar potencies and antagonism at 5-HT 2A and noradrenaline alpha 1B/2C receptors. The unique profile of SDAM might be beneficial not only in symptom control, but well tolerated with minimal metabolic and activating side effects for short and long-term use. 2 Beyond its efficacy on depressive symptoms control, antipsychotic augmentation may improve patient life engagement, thereby helping patients with MDD to achieve personally meaningful functional outcomes. 1 Thus, taking into consideration of life engagement in MDD treatment may support the development of new treatments (also identify existing treatments) that can help patients to achieve their personal treatment goals in clinical practice, in addition to improving core depressive symptoms. 3 This lecture would be beneficial in providing in-depth scientific and clinical interventions for Hong Kong Psychiatrists to spotlight antipsychotic augmentation for MDD patients with inadequate response.

Lecture 3: Translating 48-Month Lecanemab Data into Real-World Practice: Advancing Precision Treatment in Alzheimer's Disease

14:30-15:15, November 9th, 2025, Sunday

Dr. CHU Yim Pui, Jonathan

Dr. Chu Yim Pui Jonathan is a well-regarded neurologist known for his expertise in diagnosing and treating various neurological disorders. He has a strong background in clinical neurology and has been involved in both patient care and research.

Education and Training
Dr. Chu completed his medical degree in The University of Hong Kong followed by specialized training in neurology in Hong Kong. He had his oversea training in Neurophysiology Department in the University of Turku in Finland. His education has equipped him with a comprehensive understanding of the nervous system and its related diseases.

Professional Affiliations
He currently works as honorary consultant neurologist in Glenealges Hospital in Hong Kong and he is the associate clinical professor in Department of Medicine & therapeutics in Chinese University of Hong Kong. Besides, he is also the director of Epilepsy foundation of Hong Kong and executive board member of the Hong Kong Epilepsy Society. All these work keeps him connected with the latest advancements and best practices in the field.

Clinical Practice
In his practice, Dr. Chu focuses on conditions such as:
- Neurodegenerative diseases
- Neurophysiology
- Epilepsy
- Stroke

Research Contributions
Dr. Chu is also active in neurological research, contributing to studies that aim to improve the understanding and treatment of neurological conditions. His published work is often featured in respected medical journals, reflecting his commitment to advancing the field.

Abstract

Soluble amyloid beta protofibrils are highly neurotoxic and arise early in Alzheimer's disease. Sustained suppression helps prevent reaccumulating and clinical worsening.
Lecanemab clears toxic amyloid beta protofibrils and rapidly removes amyloid plaques, with a lower cerebral amyloid angiopathy binding profile and reduced amyloid-related imaging abnormalities with edema risk. Stopping lecanemab after 18 months leads to rapid rebound in amyloid beta 42/40 biomarkers and rising amyloid positron emission tomography signal, with placebo-like decline (Study 201). In the CLARITY AD open-label extension to 48 months, continuous treatment delivered durable benefits: 81.4% remained in mild cognitive impairment or mild Alzheimer's disease dementia, with slowing on the Clinical Dementia Rating–Sum of Boxes and delayed progression versus external cohorts. Early-stage, low-tau participants benefited most: at 48 months, 69% had no Clinical Dementia Rating–Sum of Boxes decline and 56% improved; at 18 months, low-tau groups showed markedly less decline across Clinical Dementia Rating–Sum of Boxes, Alzheimer's Disease Assessment Scale–Cognitive Subscale 14, and Alzheimer's Disease Cooperative Study–Mild Cognitive Impairment–Activities of Daily Living.
Evidence supports continuous lecanemab to maintain protofibril suppression, prevent biomarker and positron emission tomography rebound, and sustain multi-year clinical benefit, especially when initiated early in low-tau patients. Monthly maintenance dosing appears critical to prevent disease reacceleration.

Lecture 4: The Gut-Brain Axis in Prodromal Synucleinopathy: Insights from a Hong Kong iRBD Cohort

15:45-16:30, November 9th, 2025, Sunday



Dr. HUANG Bei, Joanne

Dr. Bei Huang is a Research Assistant Professor in the Department of Psychiatry at The Chinese University of Hong Kong. She completed her medical training with honours at Soochow University and her postgraduate neurology training at the Naval Medical University, China, before earning a PhD in Medical Sciences from CUHK in 2021. She further honed her expertise as a postdoctoral fellow at CUHK before assuming her current faculty position in 2023.

With over eight years of experience, Dr. Huang's research spans the epidemiology, pathophysiology, and diagnosis of neurodegenerative diseases and sleep disorders including narcolepsy and REM sleep behavior disorder (RBD). Her current research interests are primarily focused on understanding the gut-brain hypothesis of Parkinson's disease pathogenesis, from gut microbiota and metabolomics, intestinal disorders, host-gut microbiota interactions, to inflammatory pathways, targeting a wide spectrum of patients at early and prodromal stages of Parkinson's disease, including RBD and their first-degree relatives. A key translational aim of her research is the development of novel gut-based diagnostic tools and therapeutics for the early identification and prevention of Parkinson's disease and other neurodegeneration. Concurrently, as a sleep specialist, she pursues research into genetic risk factors for RBD as well as polysomnography related analysis, including the characterization of nocturnal behaviors and their dream correlates in patients with RBD and prodromal RBD. Dr. Huang's research is funded by competitive grants including HMRF, RGC-GRF and CUHK Direct grants. She has published more than 20 research articles in prestigious journals, including Nature Communications, Annals of Neurology, and Journal of Neurology, Neurosurgery and Psychiatry.

Abstract

Alpha-synucleinopathies, such as Parkinson's disease (PD), dementia with Lewy bodies, and multiple system atrophy, are neurodegenerative disorders defined by the pathological aggregation of alpha-synuclein (-syn) in the central and peripheral nervous systems. Accumulating evidence implicates the gut-brain axis as a critical pathway in their pathogenesis. Prevailing hypotheses suggest that gut dysbiosis, intestinal inflammation, and disrupted barrier function may initiate -syn misfolding in the enteric nervous system, facilitating its prion-like spread to the brain via the vagus nerve.

However, as a vital organ of the human body, the gut microbiome is a large, complex and mysterious community in which its composition and functionality are closely related to many extrinsic and intrinsic factors of the host (e.g., lifestyle and physiological variables). Despite the discovery of gut dysbiosis, it is still difficult to truly explore disease-specific alterations and precise targets for intervention. Isolated REM sleep behavior disorder (iRBD) serves as a powerful prodromal model for different phenotypes of alpha-synucleinopathies, with over 80% of patients progressing to overt synucleinopathy within 13 years. Critically, PD-like gut dysbiosis is already present in patients with iRBD and their high-risk relatives, offering a unique window for early investigation.

This talk will synthesize current research on the gut-brain axis in alpha-synucleinopathies, with a focus on iRBD. We will present our foundational work from a large-scale iRBD cohort in Hong Kong, which characterizes gut microbial alterations and their correlations with lifestyle factors and neurodegenerative markers. Furthermore, we will discuss how the microbiota-gut-brain axis relates to clinical heterogeneity, such as the co-occurrence of RBD and depression. Moving forward, future research is expected to prioritize longitudinal studies and deeper mechanistic inquiries to elucidate the role of gut-brain axis, validate potential gut-based interventions (e.g., probiotics, dietary strategies), and develop robust, gut-derived biomarkers for early risk stratification and prevention.

Notes to Delegates

Meeting Organizer
Hong Kong Society of Biological Psychiatry

Meeting Secretariat
c/o One Beautiful Thing
Tel: +852 9420 5529
E-mail: conference.hksbp@gmail.com

Meeting Date
November 8-9th 2025, Saturday and Sunday

Meeting Venue
4/F, Bauhinia Room, Marco Polo Hong Kong Hotel, Harbour City, 3 Canton Road, Tsim Sha Tsui

On-site Registration
The registration counter is located at the entrance of Bauhinia Room.
For on-site registration, payment must be made in cash in HK dollars.

Registration Fees:

HKSBP Members	Free of charge
Non-HKSBP Members	HKD 450
Students*	HKD 50

*It is limited to Undergraduates & Postgraduates of Neuro-science, Mental Health and Medicine related subjects. An official document from the appropriate department for verification is required.

Registration Entitlement
Fully registered participants are entitled to:
- Entry to all scientific sessions
- Visit the exhibition
- A full set of official publications
- A certificate of attendance
- Attend the lunch & dinner symposia and tea refreshments

Identification Badge
Each participant will receive a badge and a programme book upon check-in. The registration counter is located at the entrance of the Bauhinia Room. Please wear your identification badge at all times during the event, as it serves as your admission to all scientific sessions, tea refreshments and lunch/ dinner.

Academic Accreditation
Continuing Medical Education (CME) credits have been applied from different medical colleges in Hong Kong. To obtain CME accreditation, please signify your attendance at the CME sign-in desk, which is located at the registration counter.

Official Language
The official language of this meeting is English. No simultaneous interpretation will be provided.

Exhibition
The exhibits are located on the same floor as the meeting venue. The opening hours of the exhibition runs from 9:30-17:00 on November 9th 2025. The dinner symposia on November 8th 2025 is sponsored by Lundbeck while the lunch symposia on November 9th, 2025 is sponsored by Otsuka. Lecture 3 on November 9th, 2025 is sponsored by Eisai.

Meal Arrangement
Dinner will be served in the Bauhinia room on November 8th 2025. Lunch will be served in the Jade and Lotus room on the 6/F on November 9th 2025, whilst tea and refreshment will be served outside of the Bauhinia room.

Insurance
The organizing committee of 2025 ASM is not responsible for personal accidents and/or damage to the property of participants. Participants should make their own arrangement for personal insurance.

Lost and Found
Please take good care of your personal belongings. Do not leave them unattended. Neither the Meeting Organizer nor the Meeting Secretariat will be responsible for any loss or damage of your personal properties. Should you require any assistance, please contact our staff at the registration counter.

Photo Taking, Audio Recording and Video Shooting
No photo taking, audio recording and video shooting are allowed in the meeting rooms unless permission is granted.

Smoking Policy
The Marco Polo Hong Kong Hotel is a smoke-free premise. No indoor smoking is allowed.

Acknowledgments

The Organizing Committee would like to extend their heartfelt thanks to the following sponsors for their generous support in making a great success of the ASM 2025.

Platinum Sponsor

Lundbeck

Gold Sponsor

Otsuka

Lecture Sponsor

Eisai

Booth Sponsor

Johnson&Johnson

DCH AURIGA

DKSH

ZUELLIG PHARMA Commercialization


將今晚の自然入睡
今晚の好眠
交給我
#可以不依賴?
#如何無反彈
#你需要
自然入睡嗎
達衛眠
DAYVIGO® 達衛眠®
Eisai
Lemborexant
28 film-coated tablets
Prescription Drug
處方藥物
Each tablet contains 5 mg of lemborexant.
5 mg
28 Tablets
衛材(香港)有限公司 Eisai (Hong Kong) Co., Ltd
地址:北角電氣道169號理文商業中心29樓A室
電話:(852) 2516-6128 傳真:(852) 2561-5042
請於使用前詳閱產品標籤說明 | 內容僅供參考,有關個別病人治療方案,詳情請向醫生查詢
HK-DG-13-002 (Sep 2025)


Spravato®
(esketamine)
nasal spray
The Missing Piece
Neuroplasticity Promoter
for your MDD patients1-4
Synergetic
Glutamate + Monoaminergic pathways - Promote BDNF release for neuroplasticity4,5
Supreme
Enhance productivity and reduce functional impairments6
Speedy
Significant efficacy shown as fast as 4 hours after administration7
Secure
Median 635 days relapse-free time for stable responders8
Safe
Generally well tolerated with transient adverse events9,10
Scan here to access the abbreviated Product Information of Spravato®:
Intended for Healthcare Professionals only.
CP-443843 Feb 2025
Abbreviations: BDNF, brain-derived neurotrophic factor; MDD, major depressive disorder.
Johnson&Johnson
Johnson & Johnson (Hong Kong) Ltd
13/F, Tower 1, Grand Century Place, 193 Prince Edward Road West, Mongkok, Kowloon, Hong Kong
© 2025 Johnson & Johnson


We invite you to join us so we can continue our work advancing biological psychiatry to improve patient care together. To join HKSBP, please scan this QR code
Scan Me


Seroquel XR®
quetiapine
ONE FOR ALL
Major Mental Disorders
GAD
BIPOLAR DEPRESSION
MDD
SCHIZOPHRENIA
BIPOLAR MANIA
APPROVED INDICATIONS
Bipolar Depression - 50-600mg/day*
Major Depressive Disorder (MDD) - 50-300mg/day*
Schizophrenia - 400-800mg/day*
Bipolar Mania - 400-800mg/day*
Generalised Anxiety Disorder (GAD) - 50-150mg/day*
* Dose range for acute treatment
ZUELLIG PHARMA
Commercialization
Zuellig Pharma Limited
5/F, Berkshire House, Taikoo Place, 25 Westlands Road, Quarry Bay, Hong Kong.
Tel : (852) 2856 3632 | Fax : (852) 2950 7186
Luye Pharma
Luye Pharma Group Ltd.
Suite 3207, Champion Tower, 3 Garden Road, Central, Hong Kong

Otsuka Pharmaceutical (H.K.) Ltd.
Rm 1801, 18/F, Lee Garden Three, 1 Sunning Road, Causeway Bay, Hong Kong.
Tel: 2881 6299 Fax: 2577 5206

Scan here for abbreviated prescribing information of REXULTI®

HKOP-REX-202509-001

Brintellix® vortioxetine

Brintellix® is indicated for the treatment of major depressive episodes in adults

75% of patients with Major Depressive Disorder (MDD) reported experiencing ANHEDONIA[1-3]

Brintellix® is an evidence-based antidepressant for ANHEDONIA that is essential to achieve FUNCTIONAL RECOVERY[2,4]

Brintellix® demonstrated a SUPERIOR EFFECT compared to agomelatine on ANHEDONIA and FUNCTIONING[5]

Brintellix® demonstrated a DOSE DEPENDENT EFFECT without compromising tolerability[5,6]

Reference: 1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 2013; 2. Cao B et al. Front Psychiatry. 2019 Jan 31; 10:17; 3. Conradi HJ, et al. Psychol Med 2011; 41: 1165-117; 4.Fagiolini A et al. J Affect Disord. 2021;283:472-479;
5. McIntyre RS, et al. Neuropsychiatr Dis Treat. 2021;17:575–585; 6.Christensen MC, et al. CNS Spectr. 2021;1-26.

Lundbeck HK Limited
Suite 4303, 43/F Central Plaza,
18 Harbour Road, Wan Chai, Hong Kong
Tel : +852 2244 8888 Tel : +852 2827 2228
www.lundbeck.com

Brintellix®
The latest Prescribing Information approved by the Department of Health in Hong Kong

HK-BRIN-0356 APR2025

NOTE

Contact Us

Hong Kong Society of Biological Psychiatry (HKSBP)
Tel: (852) 9609 6064
Email: secretariat@hksbp.org
Website http://www.hksbp.org